%0 Journal Article
%T Long-Term Metformin Effect on Endometrial Cancer Development Depending on Glucose Environment <i>In Vitro</i>
%A Amanda Machado Weber
%A Carsten Lange
%A Julia Jauckus
%A Thomas Strowitzki
%A Ariane Germeyer
%J Open Journal of Obstetrics and Gynecology
%P 1172-1189
%@ 2160-8806
%D 2021
%I Scientific Research Publishing
%R 10.4236/ojog.2021.119111
%X <strong>Objectives:</strong><span><span><span style=\"font-family:&quot;\"><strong>&nbsp;</strong></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">Hyperinsulinemia as well as prolonged and elevated estrogen exposure are
considered as risk factors for endometrial cancer (EC) development.</span></span></span></span><span><span><span><span style=\"font-family:&quot;\"> </span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">Metformin, an anti-hyperglycemic and
insulin-sensitizing biguanide, displayed anti-proliferative effects in recent
studies. </span></span></span></span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\">In the present study, the effects of long-term
exposure of endometrial cancer cells to low and moderate concentrations of
metformin on cell viability, proliferation, clonogenicity and migration were
investigated under different metabolic conditions. </span><b><span style=\"font-family:Verdana;\">Study Design:</span></b></span></span></span><span><span><b><span style=\"font-family:&quot;\"> </span></b></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">EC cell lines HEC-1A and Ishikawa were cultured
under normo</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">- </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">(NG, 5.5
mM) or hyperglycemic (HG, 17.0 mM) conditions and treated with metformin (0.01</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> - </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">5.0 mM) in the presence of</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><i><span style=\"font-family:Verdana;\">¦Â</span></i></span></span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\">-estradiol (E2) for 7 d. </span><b><span style=\"font-family:Verdana;\">Results:</span></b></span></span></span><span><span><b><span
%K Metformin
%K Endometrial Cancer
%K Proliferation
%K Migration
%K Clonogenicity
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=111964